Geode Capital Management’s Cognition Therapeutics CGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding CGTX
BCM
DC
HCM
CM
DIG
SPC
Geode Capital Management's CGTX Position: Q2 2026 in Review
Geode Capital Management reduced its Cognition Therapeutics (CGTX) stake by 1.1% in Q2 2026, selling an estimated $12.1K and leaving 910,006 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #3348.
Geode Capital Management first reported a position in CGTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.18M in Q4 2025. 64 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.
- Geode Capital Management held 910,006 shares of Cognition Therapeutics worth $1.05M as of Q2 2026.
- Geode Capital Management sold 10,202 Cognition Therapeutics shares in Q2 2026, an estimated $12.1K.
- Cognition Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3348 holding.
- Geode Capital Management first reported a position in Cognition Therapeutics in Q1 2022 and has held it in 18 quarters since.
- Geode Capital Management's Cognition Therapeutics position peaked at $1.18M in Q4 2025.
- 64 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.